India Immuno-Oncology Drugs Market, by Drug Type (Immune Checkpoint Inhibitors (Nivolumab, Atezolimumab, Pembrolizumab, Durvalumab), Monoclonal Antibodies (Rituximab, Trastazumab, Bevacizumab , Nimotuzumab, Pertuzumab, Ado-Trastuzumab Emtansine ), and Can
Description
India Immuno-Oncology Drugs Market, by Drug Type (Immune Checkpoint Inhibitors (Nivolumab, Atezolimumab, Pembrolizumab, Durvalumab), Monoclonal Antibodies (Rituximab, Trastazumab, Bevacizumab , Nimotuzumab, Pertuzumab, Ado-Trastuzumab Emtansine ), and Cancer Vaccines (Gardasil, Cervarix), by Cancer Type (Lung Cancer, Blood Cancer, Breast Cancer, Ovarian Cancer, Cervical Cancer, Colorectal Cancer, Stomach Cancer, Head & Neck Cancer, and Others), and by Distribution Channel (Online Pharmacies, Retail Pharmacies, and Hospital Pharmacies) - Size, Share, Outlook, and Opportunity Analysis, 2021 - 2028
Immuno-Oncology also known as cancer immunotherapy, is a form of cancer treatment that utilizes immune system of the body to manage, prevent, and destroy cancer. Immuno-oncologists are growing and becoming a part of cancer care group by rapidly increasing the cancer care area. The researchers did study on how to attack cancer by the immune system. Some of them work in labs on creating new treatments and some of them interact between the immune system and cancer cells.
India immuno-oncology drugs market is estimated to be valued at US$ 265 Mn in 2021 and is expected to increase to US$ 550 Mn by 2028, exhibiting a CAGR of 13.1% over the forecast period.
Market Dynamics
The rising incidence of cancer, introduction of novel immuno-oncology therapies with lesser side effects, increasing government engagement to increase cancer diagnosis, and increasing adoption of inorganic growth strategies such as mergers, acquisitions, partnerships, and collaborations by key players operating in the market are the major factors that are expected to drive the growth of the Indian immuno-oncology drugs market over the forecast period.
According to the National Cancer Registry Programme (NCRP), India, one woman dies of cervical cancer every 8 minutes in India. For every 2 women newly diagnosed with breast cancer, one woman dies of it in India. Furthermore, as many people die every day due to tobacco-related cancer diseases in India. Tobacco (smoked and smokeless) use accounted for around 317,928 deaths in men and women, in 2018.
Moreover, The WHO also suggested that people with low and middle income countries should have necessary data for cancer policies because of lack of awareness for treatment availability.
Key features of the study:
Immuno-Oncology also known as cancer immunotherapy, is a form of cancer treatment that utilizes immune system of the body to manage, prevent, and destroy cancer. Immuno-oncologists are growing and becoming a part of cancer care group by rapidly increasing the cancer care area. The researchers did study on how to attack cancer by the immune system. Some of them work in labs on creating new treatments and some of them interact between the immune system and cancer cells.
India immuno-oncology drugs market is estimated to be valued at US$ 265 Mn in 2021 and is expected to increase to US$ 550 Mn by 2028, exhibiting a CAGR of 13.1% over the forecast period.
Market Dynamics
The rising incidence of cancer, introduction of novel immuno-oncology therapies with lesser side effects, increasing government engagement to increase cancer diagnosis, and increasing adoption of inorganic growth strategies such as mergers, acquisitions, partnerships, and collaborations by key players operating in the market are the major factors that are expected to drive the growth of the Indian immuno-oncology drugs market over the forecast period.
According to the National Cancer Registry Programme (NCRP), India, one woman dies of cervical cancer every 8 minutes in India. For every 2 women newly diagnosed with breast cancer, one woman dies of it in India. Furthermore, as many people die every day due to tobacco-related cancer diseases in India. Tobacco (smoked and smokeless) use accounted for around 317,928 deaths in men and women, in 2018.
Moreover, The WHO also suggested that people with low and middle income countries should have necessary data for cancer policies because of lack of awareness for treatment availability.
Key features of the study:
- This report provides an in-depth analysis of the India immuno-oncology drugs market provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2021–2028), considering 2020 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the India immuno-oncology drugs market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
- Key companies covered as a part of this study include Amgen Inc., F. Hoffmann-La Roche AG., Intas Pharmaceuticals Ltd., AstraZeneca plc, Mylan N.V., Dr. Reddy's Laboratories, Bristol - Myers Squibb, Merck & Co., Inc., BIOCAD-Biotechnology company, Reliance Life Sciences, Biocon Limited, and Hetero Drugs Limited
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The India immuno-oncology drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the India immuno-oncology drugs market
- India Immuno-Oncology Drugs Market, Drug Type:
- Immune Checkpoint Inhibitors
- Nivolumab
- Atezolimumab
- Pembrolizumab
- Durvalumab
- Monoclonal Antibodies
- Rituximab
- Trastazumab
- Bevacizumab
- Nimotuzumab
- Pertuzumab
- Ado-Trastuzumab Emtansine
- Cancer Vaccines
- Gardasil
- Cervarix
- India Immuno-Oncology Drugs Market, Cancer Type:
- Lung cancer
- Blood cancer
- Breast cancer
- Ovarian cancer
- Cervical cancer
- Colorectal cancer
- Stomach cancer
- Head & Neck cancer
- Others
- India Immuno-Oncology Drugs Market, Distribution Channel:
- Online Pharmacies
- Retail Pharmacies
- Hospital Pharmacies
- Company Profiles:
- Amgen, Inc. *
- Company highlights
- Product Portfolio
- Key Highlights
- Financial performance
- Strategies
- F. Hoffmann-La Roche AG.
- Intas Pharmaceuticals Ltd.
- AstraZeneca plc
- Mylan N.V.
- Dr. Reddy's Laboratories
- Bristol - Myers Squibb
- Merck & Co., Inc.
- BIOCAD-Biotechnology company
- Reliance Life Sciences
- Biocon Limited
- Hetero Drugs Limited
Table of Contents
162 Pages
- 1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
- 2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Product Type
- Market Snippet, By Drug Class
- Market Snippet, By Route of Administration
- Market Snippet, By End Users
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
- 3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Product approval and launches
- Merges and Acquisitions
- Key development
- Middle East and Asia drug approval process
- Regulatory Scenario
- Reimbursement Scenario
- Brand Analysis
- PEST Analysis
- Pricing Analysis
- Technology Advancement
- 4. Middle East and Asia Injectable Drugs Market – Impact of Coronavirus (COVID-19) Pandemic
- Economic Impact
- Impact on Clinical Trials and Drug Development
- Government Initiatives
- 5. Middle East and Asia Injectable Drugs Market, By Product Type, 2017 – 2028, (US$ Mn)
- Introduction
- Market Share Analysis, 2021 and 2028 (%)
- Y-o-Y Growth Analysis, 2018 – 2028
- Segment Trends
- Pre-filled Syringes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- Vaccines
- Blood Stimulants
- Biologics
- Others
- Auto-injectors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- Pre-filled Pens
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- Pre-mixed IV Bags
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- Sedative Products (Sedation)
- Anesthesia Products (Anesthesia)
- Pain Management Products (Post-operative analgesic pain management)
- Chemotherapy Products (Chemotherapy)
- Antibacterial Products (Infectious diseases)
- Electrolyte and Nutrition Products (Electrolyte and Nutrition)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- 6. Middle East and Asia Injectable Drugs Market, By Route of Administration, 2017 – 2028, (US$ Mn)
- Introduction
- Market Share Analysis, 2021 and 2028 (%)
- Y-o-Y Growth Analysis, 2018 – 2028
- Segment Trends
- Intravenous (IV)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- Intramuscular (IM)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- Subcutaneous (SC)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- Others (Epidural and Intrathecal)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- 7. Middle East and Asia Injectable Drugs Market, By Drug Class , 2017 – 2028, (US$ Mn)
- Introduction
- Market Share Analysis, 2021 and 2028 (%)
- Y-o-Y Growth Analysis, 2018 – 2028
- Segment Trends
- Anesthesia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- Antibiotics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- Antidotes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- Antiemetic
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- Anti-infective
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- Anti-thrombolytic
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- Muscle Relaxant
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- Non Opioids
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- Opioids
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- Sedatives
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- 8. Middle East and Asia Injectable Drugs Market, By End Users, 2017 – 2028, (US$ Mn)
- Introduction
- Market Share Analysis, 2021 and 2028 (%)
- Y-o-Y Growth Analysis, 2018 – 2028
- Segment Trends
- Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- Ambulatory Surgery Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- 9. Middle East and Asia Injectable Drugs Market, By Country, 2017 – 2028, (US$ Mn)
- Introduction
- Market Share Analysis, By Region, 2021 and 2028 (%)
- Y-o-Y Growth Analysis, For Regions, 2018–2028
- Country Trends
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017 – 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 – 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 – 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By End Users, 2017 – 2028, (US$ Mn)
- Asia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017 – 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 – 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 – 2028, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By End-Users, 2017 – 2028, (US$ Mn)
- 10. Competitive Landscape
- Heat Map Analysis
- Market Share Analysis
- Kalbe Farma
- Company highlights
- Product Portfolio
- Key Highlights
- Financial performance
- Strategies
- Pfizer Inc.
- Company highlights
- Product Portfolio
- Key Highlights
- Financial performance
- Strategies
- Novo Nordisk A/S
- Company highlights
- Product Portfolio
- Key Highlights
- Financial performance
- Strategies
- Takeda Pharmaceutical Co. Ltd.
- Company highlights
- Product Portfolio
- Key Highlights
- Financial performance
- Strategies
- Livzon Pharmaceutical Group, Inc.
- Company highlights
- Product Portfolio
- Key Highlights
- Financial performance
- Strategies
- Sun Pharmaceutical Industries, Ltd.
- Company highlights
- Product Portfolio
- Key Highlights
- Financial performance
- Strategies
- Sanofi
- Company highlights
- Product Portfolio
- Key Highlights
- Financial performance
- Strategies
- Novartis
- Company highlights
- Product Portfolio
- Key Highlights
- Financial performance
- Strategies
- Tabuk
- Company highlights
- Product Portfolio
- Key Highlights
- Financial performance
- Strategies
- GlaxoSmithKline plc
- Company highlights
- Product Portfolio
- Key Highlights
- Financial performance
- Strategies
- AstraZeneca
- Company highlights
- Product Portfolio
- Key Highlights
- Financial performance
- Strategies
- Gerresheimer AG
- Company highlights
- Product Portfolio
- Key Highlights
- Financial performance
- Strategies
- 11. Section
- References
- Research Methodology
- About Us and Sales Contact
- *Browse 30 market data tables and 35 figures on "Middle East and Asia Injectable Drugs Market” - forecast to 2028
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
